OR WAIT null SECS
In a partnership with Thermo Fisher Scientific Pharma Services, Pacira added a manufacturing suite in Swindon, UK, that doubles the company’s capacity by mirroring the company’s facility in San Diego, CA.
Pacira Pharmaceuticals announced in a Feb. 12, 2019 release that commercial production of Exparel (bupivacaine liposome injectable suspension) is now underway at a custom suite in Swindon, UK, created under the company’s partnership with Thermo Fisher Scientific Pharma Services (formerly Patheon UK Limited).
This suite was designed to mirror the company’s existing facility at the Pacira Science Center Campus in San Diego, CA, and is expected to double the company’s manufacturing capacity. Through the partnership, the companies are developing a second dedicated suite that is expected to enable another doubling of Exparel manufacturing capacity in approximately two years. The company’s investment in this facility is an integral component of its strategy to meet the growing customer demand in the US and to support expansion into new global markets, such as Europe and Asia.
“Launching this new manufacturing site marks an important milestone for Pacira and advances our commitment to providing an opioid alternative to as many surgical patients as possible,” said Dave Stack, chairman and CEO of Pacira, in a press release.